228 related articles for article (PubMed ID: 25370416)
1. Disruption of IKAROS activity in primitive chronic-phase CML cells mimics myeloid disease progression.
Beer PA; Knapp DJ; Miller PH; Kannan N; Sloma I; Heel K; Babovic S; Bulaeva E; Rabu G; Terry J; Druker BJ; Loriaux MM; Loeb KR; Radich JP; Erber WN; Eaves CJ
Blood; 2015 Jan; 125(3):504-15. PubMed ID: 25370416
[TBL] [Abstract][Full Text] [Related]
2. Ex vivo expansion of normal and chronic myeloid leukemic stem cells without functional alteration using a NUP98HOXA10homeodomain fusion gene.
Sloma I; Imren S; Beer PA; Zhao Y; Lecault V; Leung D; Raghuram K; Brimacombe C; Lambie K; Piret J; Hansen C; Humphries RK; Eaves CJ
Leukemia; 2013 Jan; 27(1):159-69. PubMed ID: 22868969
[TBL] [Abstract][Full Text] [Related]
3. KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors.
Corbin AS; O'Hare T; Gu Z; Kraft IL; Eiring AM; Khorashad JS; Pomicter AD; Zhang TY; Eide CA; Manley PW; Cortes JE; Druker BJ; Deininger MW
Cancer Res; 2013 Sep; 73(18):5775-86. PubMed ID: 23887971
[TBL] [Abstract][Full Text] [Related]
4. C/EBPβ promotes BCR-ABL-mediated myeloid expansion and leukemic stem cell exhaustion.
Hayashi Y; Hirai H; Kamio N; Yao H; Yoshioka S; Miura Y; Ashihara E; Fujiyama Y; Tenen DG; Maekawa T
Leukemia; 2013 Mar; 27(3):619-28. PubMed ID: 22948537
[TBL] [Abstract][Full Text] [Related]
5. Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL.
Aljedai A; Buckle AM; Hiwarkar P; Syed F
PLoS One; 2015; 10(4):e0123016. PubMed ID: 25849484
[TBL] [Abstract][Full Text] [Related]
6. Differential contributions of STAT5A and STAT5B to stress protection and tyrosine kinase inhibitor resistance of chronic myeloid leukemia stem/progenitor cells.
Casetti L; Martin-Lannerée S; Najjar I; Plo I; Augé S; Roy L; Chomel JC; Lauret E; Turhan AG; Dusanter-Fourt I
Cancer Res; 2013 Apr; 73(7):2052-8. PubMed ID: 23400594
[TBL] [Abstract][Full Text] [Related]
7. BCR-ABL1 induces aberrant splicing of IKAROS and lineage infidelity in pre-B lymphoblastic leukemia cells.
Klein F; Feldhahn N; Herzog S; Sprangers M; Mooster JL; Jumaa H; Müschen M
Oncogene; 2006 Feb; 25(7):1118-24. PubMed ID: 16205638
[TBL] [Abstract][Full Text] [Related]
8. IKAROS isoform 6 enhances BCR-ABL1-mediated proliferation of human CD34+ hematopoietic cells on stromal cells.
Suzuki K; Ono R; Ohishi K; Masuya M; Kataoka I; Liu B; Nakamori Y; Ino K; Monma F; Hamada H; Kitamura T; Katayama N; Nosaka T
Int J Oncol; 2012 Jan; 40(1):53-62. PubMed ID: 21901249
[TBL] [Abstract][Full Text] [Related]
9. Dominant-negative IKAROS enhances IL-3-stimulated signaling in wild-type but not BCR-ABL1(+) mouse BA/F3 cells.
von Palffy S; Bulaeva E; Babovic S; Kannan N; Knapp DJ; Wei L; Eaves CJ; Beer PA
Exp Hematol; 2015 Jul; 43(7):514-23.e1-2. PubMed ID: 25951974
[TBL] [Abstract][Full Text] [Related]
10. Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.
Pietarinen PO; Eide CA; Ayuda-Durán P; Potdar S; Kuusanmäki H; Andersson EI; Mpindi JP; Pemovska T; Kontro M; Heckman CA; Kallioniemi O; Wennerberg K; Hjorth-Hansen H; Druker BJ; Enserink JM; Tyner JW; Mustjoki S; Porkka K
Oncotarget; 2017 Apr; 8(14):22606-22615. PubMed ID: 28186983
[TBL] [Abstract][Full Text] [Related]
11. Differences in BCL-X(L) expression and STAT5 phosphorylation in chronic myeloid leukaemia patients.
Gutiérrez-Castellanos S; Cruz M; Rabelo L; Godínez R; Reyes-Maldonado E; Riebeling-Navarro C
Eur J Haematol; 2004 Apr; 72(4):231-8. PubMed ID: 15089759
[TBL] [Abstract][Full Text] [Related]
12. BCR/ABL-negative primitive progenitors suitable for transplantation can be selected from the marrow of most early-chronic phase but not accelerated-phase chronic myelogenous leukemia patients.
Verfaillie CM; Bhatia R; Miller W; Mortari F; Roy V; Burger S; McCullough J; Stieglbauer K; Dewald G; Heimfeld S; Miller JS; McGlave PB
Blood; 1996 Jun; 87(11):4770-9. PubMed ID: 8639848
[TBL] [Abstract][Full Text] [Related]
13. Stage specific over-expression of the dominant negative Ikaros 6 reveals distinct role of Ikaros throughout human B-cell differentiation.
Tonnelle C; Dijon M; Moreau T; Garulli C; Bardin F; Chabannon C
Mol Immunol; 2009 May; 46(8-9):1736-43. PubMed ID: 19285729
[TBL] [Abstract][Full Text] [Related]
14. The Ikaros splice isoform, Ikaros 6, immortalizes murine haematopoietic progenitor cells.
Ruiz A; Williams O; Brady HJ
Int J Cancer; 2008 Sep; 123(6):1240-5. PubMed ID: 18623087
[TBL] [Abstract][Full Text] [Related]
15. The kinetics and extent of engraftment of chronic myelogenous leukemia cells in non-obese diabetic/severe combined immunodeficiency mice reflect the phase of the donor's disease: an in vivo model of chronic myelogenous leukemia biology.
Dazzi F; Capelli D; Hasserjian R; Cotter F; Corbo M; Poletti A; Chinswangwatanakul W; Goldman JM; Gordon MY
Blood; 1998 Aug; 92(4):1390-6. PubMed ID: 9694728
[TBL] [Abstract][Full Text] [Related]
16. Rationally designed aberrant kinase-targeted endogenous protein nanomedicine against oncogene mutated/amplified refractory chronic myeloid leukemia.
Retnakumari AP; Hanumanthu PL; Malarvizhi GL; Prabhu R; Sidharthan N; Thampi MV; Menon D; Mony U; Menon K; Keechilat P; Nair S; Koyakutty M
Mol Pharm; 2012 Nov; 9(11):3062-78. PubMed ID: 22971013
[TBL] [Abstract][Full Text] [Related]
17. Sudden blast phase in pediatric chronic myeloid leukemia-chronic phase with abnormal lymphoid blasts detected by flow cytometry at diagnosis: Can it be considered a warning sign?
Vijayasekharan K; Chatterjee G; Ramanathan S; Narula G; Tembhare P; Subramanian PG; Patkar N; Gujral S; Shetty D; Banavali S
Cytometry B Clin Cytom; 2021 May; 100(3):345-351. PubMed ID: 33030302
[TBL] [Abstract][Full Text] [Related]
18. A dominant-negative isoform of IKAROS expands primitive normal human hematopoietic cells.
Beer PA; Knapp DJ; Kannan N; Miller PH; Babovic S; Bulaeva E; Aghaeepour N; Rabu G; Rostamirad S; Shih K; Wei L; Eaves CJ
Stem Cell Reports; 2014 Nov; 3(5):841-57. PubMed ID: 25418728
[TBL] [Abstract][Full Text] [Related]
19. Genotypic and functional diversity of phenotypically defined primitive hematopoietic cells in patients with chronic myeloid leukemia.
Sloma I; Beer PA; Saw KM; Chan M; Leung D; Raghuram K; Brimacombe C; Johnston B; Lambie K; Forrest D; Jiang X; Eaves CJ
Exp Hematol; 2013 Oct; 41(10):837-47. PubMed ID: 23851302
[TBL] [Abstract][Full Text] [Related]
20. Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis.
Zheng C; Li L; Haak M; Brors B; Frank O; Giehl M; Fabarius A; Schatz M; Weisser A; Lorentz C; Gretz N; Hehlmann R; Hochhaus A; Seifarth W
Leukemia; 2006 Jun; 20(6):1028-34. PubMed ID: 16617318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
